Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas
Sign Up to like & getrecommendations! Published in 2020 at "Acta Oncologica"
DOI: 10.1080/0284186x.2020.1762925
Abstract: Abstract Purpose: Ruthenium-106 (Ru-106) brachytherapy is a common eye-preserving treatment for choroidal melanomas. However, a dose-response model describing the relationship between the actual delivered tumour dose and tumour control has, to the best of our… read more here.
Keywords: dose; control; 106 brachytherapy; ruthenium 106 ... See more keywords